Loading
Carrick Therapeutics
Carrick Therapeutics develops medicines taken by mouth that block enzymes cancer cells use to grow. Its lead drug, samuraciclib, is being tested with hormone therapy in advanced hormone receptor-positive, HER2-negative breast cancer after earlier treatment has stopped working.
Also called: Carrick Therapeutics, Inc.Carrick Therapeutics Limited
Overview
Carrick Therapeutics is a clinical-stage oncology company whose lead programme is samuraciclib (CT7001), an oral CDK7 inhibitor discovered at Imperial College London with Cancer Research UK funding. Its main indication is HR-positive, HER2-negative advanced breast cancer after a CDK4/6 inhibitor. In the randomised phase 2 SUMIT-BC trial (NCT05963984, 60 patients) of samuraciclib with fulvestrant against fulvestrant alone, the company reported in December 2025 an overall response rate of 33% versus 14% and median progression-free survival of 7.8 versus 5.6 months in all patients, with larger differences in patients without a TP53 mutation (a pre-specified group), and said it plans a phase 3 trial in 2026. Samuraciclib has also been combined with elacestrant and with vepdegestrant, and the company reports FDA Fast Track designations in CDK4/6 inhibitor-resistant HR-positive breast cancer and in triple-negative breast cancer. Its second programme, CT7439, is an oral CDK12/13 inhibitor that also acts as a molecular glue degrader of cyclin K, in a phase 1/2 trial in solid tumours (NCT06600789). The company has clinical collaborations with Pfizer, Roche, Menarini and Arvinas. It moved its headquarters from Dublin to Boston in June 2024 and keeps teams in Ireland and the UK.
Headquarters
Boston, MA, US
Scorecard
All companies#405of 1706 companies, score 11
- phase 1/2 +2
- targets +2
- modalities +2
- registry trials +5
0 approved, 0 in phase 3, 2 earlier, 1 targets, 6 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors
Type
Stage
Startup
Website
Products
2Phase 2Oral CDK inhibitor
Samuraciclib is an oral cdk inhibitor from Pfizer, in registered phase 2 trials for metastatic cancer, HR-positive / HER2-negative breast cancer.
Phase 1Small molecule, oral
CT7439 is an experimental pill from Carrick Therapeutics, in phase 1 trials for advanced solid tumours.
Notes
- Founding year not stated on the pages read; omitted.
- CDK7 and CDK13 are not OnCo target records; only CDK12 is linked. Cyclin K (CCNK) is also not an OnCo target.
- Samuraciclib already exists in OnCo as drug `samuraciclib`; the company should be linked from it. Samuraciclib trials NCT05963984, NCT05963997 and NCT03363893 (Carrick-sponsored) are not OnCo trial records yet.
- The company says samuraciclib could also be used in prostate, pancreatic, small cell lung, ovarian and colorectal cancer; these are not linked because there is no named programme.
Connected
9Similar pages
- TrialTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
Shares Samuraciclib, PROTACs & molecular glues (targeted protein degradation).
- TrialA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Shares Samuraciclib, HR-positive / HER2-negative breast cancer.
- CompanyBoundless Bio
Shares ARCH Venture Partners, PROTACs & molecular glues (targeted protein degradation), HR-positive / HER2-negative breast cancer.
- TrialA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
- PersonJosé Baselga
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
- CompanyParabilis Medicines
Shares ARCH Venture Partners, PROTACs & molecular glues (targeted protein degradation).
- TrialA Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
- TrialA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Shares HR-positive metastatic breast cancer after CDK4/6 inhibitors, HR-positive / HER2-negative breast cancer.
cancers
fronts
technologies
targets
drugs
Phase 1Small molecule, oral
Phase 2Oral CDK inhibitor
companies
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
carricktherapeutics.com · 6
archive.org · 1
A source that has moved or gone is reported by the weekly link check. /audit/